The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Comparison of the efficacy and safety under integrated treatment to diabetic patients with peripheral artery disease between ozagrel sodium and low molecular heparin calcium
Author(s): 
Pages: 412-415
Year: Issue:  7
Journal: World Clinical Drugs

Keyword:  奥扎格雷钠低分子肝素钙糖尿病下肢动脉病变收缩期峰值血流速度踝肱指数(ABI);
Abstract: 目的 观察奥扎格雷钠和低分子肝素钙治疗糖尿病下肢动脉疾病的疗效和安全性.方法 64例糖尿病伴下肢严重动脉狭窄的患者,随机分为奥扎格雷钠组和低分子肝素钙治疗组,所有患者在全身情况稳定的基础上,分别接受奥扎格雷钠和低分子肝素钙治疗2周,观察治疗前后腘动脉收缩期峰值血流速度(PSV)和踝肱指数(ABI),安全性评估指标包括活化部分凝血酶时间(APTT)和凝血酶原时间(PT).结果 两组患者治疗前后腘动脉PSV变化值比较差异显著,其中奥扎格雷钠组PSV增加(7.29±8.81)cm/s,低分子肝素钙组PSV增加(13.55±13.11)cm/s,组间差异具有统计学意义(P<0.05);两组治疗前后ABi变化值分别为(0.07±0.07)和(0.08±0.06),组间差异具有统计学意义(P<0.05):但两组患者治疗前后APTT和PT比较差异均无统计学意义.且药物不良反应轻.结论 两种抗凝治疗均能显著改善糖尿病下肢动脉血流,且低分子肝素钙疗效优于奥扎格雷钠.
Related Articles
No related articles found